No Data
No Data
Orthocell Secures Market Clearance for Dental Regenerative Product in Canada; Shares Rise 4%
Orthocell (ASX:OCC) secured approval from medical regulator Health Canada to market and sell its dental bone regeneration product Striate+ in the Canadian market, according to a Thursday filing with
Orthocell's Market-leading Medical Devices Deliver Record Quarterly and Full Year Sales
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has delivered record revenue for the June quarter and for the 2024 financial year as it experiences continuing impressive sales growth of its market-leading medical devices, Striate+™ and Remplir™.
The Past Three Years for Orthocell (ASX:OCC) Investors Has Not Been Profitable
Orthocell Files Application With Therapeutic Goods Administration for Tendon Repair Product; Shares Rise 3%
Orthocell (ASX:OCC) applied with the Australian medical regulator Therapeutic Goods Administration to market and sell the SmrtGraft product for tendon repair and regeneration, according to a Tuesday f
Orthocell's Striate+ Dental Membrane Product Achieves 98.6% Success Rate in Post-Market Clinical Study; Shares Up 3%
Orthocell (ASX:OCC) said a post-market clinical study evaluating the effect of Striate+ in dental implant treatment for guided bone regeneration resulted in a 98.6% success rate, according to a Tuesda
Orthocell Fortifies Cash Position for US Expansion With A$3.05 Million R&D Tax Refund
Leading regenerative medicine company Orthocell Ltd (ASX:OCC, OTC:ORHHF) has secured an Australian Research and Development (R&D) Tax Incentive refund amounting to A$3.05 million for the fiscal year 2022-2023.
No Data